GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,420.60p
   
  • Change Today:
    -0.40p
  • 52 Week High: 2,263.00
  • 52 Week Low: 1,296.00
  • Currency: UK Pounds
  • Shares Issued: 4,094.93m
  • Volume: 3,347,274
  • Market Cap: £58,173m
  • RiskGrade: 129

GSK cancer treatment meets trial endpoint

By Frank Prenesti

Date: Friday 02 Dec 2022

LONDON (ShareCast) - (Sharecast News) - GSK on Friday unveiled positive headline results from a Phase 3 trial of its Jemperli endometrial cancer drug.


The company said Jemperli met its primary endpoint of investigator-assessed progression-free survival (PFS) and showed a "statistically significant and clinically meaningful benefit".

Endometrial cancer is found in the inner lining of the uterus, known as the endometrium. It is the most common gynaecologic cancer in the US and the second most common gynaecologic cancer globally.

Approximately 15-20% of women with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis.

Reporting by Frank Prenesti for Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,420.60p
Change Today -0.40p
% Change -0.03 %
52 Week High 2,263.00
52 Week Low 1,296.00
Volume 3,347,274
Shares Issued 4,094.93m
Market Cap £58,173m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
70.51% below the market average70.51% below the market average70.51% below the market average70.51% below the market average70.51% below the market average
1.69% above the sector average1.69% above the sector average1.69% above the sector average1.69% above the sector average1.69% above the sector average
Price Trend
9.94% below the market average9.94% below the market average9.94% below the market average9.94% below the market average9.94% below the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average
Income
39.28% above the market average39.28% above the market average39.28% above the market average39.28% above the market average39.28% above the market average
77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average
Growth
51.26% below the market average51.26% below the market average51.26% below the market average51.26% below the market average51.26% below the market average
52.38% below the sector average52.38% below the sector average52.38% below the sector average52.38% below the sector average52.38% below the sector average

What The Brokers Say

Strong Buy 3
Buy 6
Neutral 13
Sell 1
Strong Sell 2
Total 25
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 23-Feb-23 17-Nov-22
Paid 13-Apr-23 12-Jan-23
Amount 13.75p 13.75p

Trades for 29-Mar-2023

Time Volume / Share Price
16:35 100 @ 1,420.60p
16:35 495 @ 1,420.60p
16:35 299 @ 1,420.60p
16:35 5,977 @ 1,420.60p
16:35 4,023 @ 1,420.60p

GSK Key Personnel

CEO Emma Walmsley
CFO Iain Mackay

Top of Page